• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Paxman

53.90 SEK

-1.64 %

Less than 1K followers

PAX

First North Stockholm

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-1.64 %
+10.00 %
+2.47 %
-4.09 %
-3.75 %
-33.78 %
+63.33 %
-0.19 %
+394.50 %

Paxman is active in scalp cooling, which is used for patients undergoing chemotherapy. The company's product Paxman Scalp Cooler is used to minimize hair loss in patients during treatment. The Scalp Cooler is a freestanding, mobile and electrically powered cooling unit that cools the patient's scalp via a cooling cap. Paxman was founded in 1996 and is headquartered in Karlshamn.

Read more
Market cap
1.25B SEK
Turnover
214.4K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
21.8.
2026

Interim report Q2'26

20.11.
2026

Interim report Q3'26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release5/22/2026, 9:05 AM

Press release from PAXMAN AB’s 2026 Annual General Meeting

Paxman
Press release5/22/2026, 5:29 AM

DNB Carnegie Access: Paxman: IBBM on track and CIPN catalyst pending – Q1 review

Paxman
Press release5/21/2026, 10:07 AM

Redeye: Paxman (Q1 Initial take): In line with expectations

Paxman

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release5/21/2026, 6:21 AM

DNB Carnegie Access: Paxman: Clean beat to start the year – Q1 initial

Paxman
Regulatory press release5/21/2026, 5:00 AM

PAXMAN publishes its interim report for Q1 2026

Paxman
Press release5/20/2026, 8:00 AM

Invitation: Live Presentation with Richard Paxman – Q1 2026

Paxman
Press release5/12/2026, 9:47 AM

Redeye: Paxman (Q1 Preview): First CPT1 quarter

Paxman
Press release4/30/2026, 7:06 AM

DNB Carnegie Access: Paxman: New year, new model – Q1 preview

Paxman
Regulatory press release4/24/2026, 5:00 AM

Paxman publishes the company’s annual report for 2025

Paxman
Regulatory press release4/20/2026, 8:00 AM

NOTICE OF ANNUAL GENERAL MEETING IN PAXMAN AB (publ)

Paxman
Press release3/2/2026, 10:19 AM

Redeye: Paxman (Q4 Review): Quarter below expectations, but IBBM development is encouraging

Paxman
Press release3/2/2026, 7:42 AM

DNB Carnegie Access: Paxman: Closing the chapter on an eventful 2026 – Q4 review

Paxman
Press release2/27/2026, 7:49 AM

DNB Carnegie Access: Paxman: Margin pressure reached its peak – Q4 initial comment

Paxman
Regulatory press release2/27/2026, 6:00 AM

PAXMAN publishes year-end report as of 31 December 2025

Paxman
Press release2/23/2026, 10:30 AM

Invitation: Live Presentation with CEO Richard Paxman – Year-end report 2025

Paxman
Press release2/23/2026, 9:53 AM

DNB Carnegie Access: Paxman: Category III CPT Codes for Cryocompression secured

Paxman
Press release2/23/2026, 9:13 AM

Redeye: Paxman: CPT-III codes for Paxman’s CIPN device

Paxman
Press release2/20/2026, 3:17 PM

Paxman Announces Category III CPT Codes for Cryocompression Therapy to Prevent Chemotherapy-Induced Peripheral Neuropathy

Paxman
Press release2/2/2026, 5:23 PM

DNB Carnegie Access: Paxman: FX pressure but growth drivers are intact – Q4 preview

Paxman
Press release12/31/2025, 12:50 PM

PAXMAN announces 510k Submission to the U.S. Food and Drug Administration (FDA) for the Paxman Cryocompression Device to Prevent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Paxman